^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    EGFR mutation + MET-CEP7 fusion

    i
    Other names: EGFR, ERBB, ERBB1, Epidermal growth factor receptor, CEP72, Centrosomal Protein 72, KIAA1519, Centrosomal Protein Of 72 KDa, Centrosomal Protein 72kDa, FLJ10565, Cep72, DFNB97, AUTS9, RCCP2, C-Met, HGFR, HGF Receptor, Met Proto-Oncogene, HGF/SF Receptor, Proto-Oncogene C-Met, Scatter Factor Receptor, Tyrosine-Protein Kinase Met, Hepatocyte Growth Factor Receptor, MET, MET Proto-Oncogene, Receptor Tyrosine Kinase
    Entrez ID:
    1956; 4233; 55722
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    11ms
    Functional Heterogeneity in MET Pathway Activation in PDX Models of Osimertinib Resistant EGFR-Driven Lung Cancer. (PubMed, Cancer Res Commun)
    Our results suggest osimertinib and savolitinib combination is most effective for osimertinib resistant EGFR-mutant tumors with MET pathway activation as evidenced by phospho-MET. As subclonal MET amplification may be evident in MET polysomy tumor progression, MET polysomy warrants close clinical follow up with phospho-MET IHC in parallel with FISH diagnostic.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    EGFR mutation • MET amplification • MET mutation • MET expression • EGFR mutation + MET-CEP7 fusion
    |
    Tagrisso (osimertinib) • Orpathys (savolitinib)
    1year
    Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib Treatment (clinicaltrials.gov)
    P2, N=47, Not yet recruiting, Samsung Medical Center
    New P2 trial
    |
    EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • MET amplification • EGFR C797S • EGFR mutation + MET-CEP7 fusion
    |
    Tepmetko (tepotinib) • Lazcluze (lazertinib)
    over1year
    Predictive Biomarkers of Response to REGN5093 to Guide Patient Selection in MET-Altered Advanced Non-small Cell Lung Cancer (IASLC-WCLC 2023)
    We report biomarkers associated with clinical response and resistance to REGN5093 which may help with screening of aNSCLC pts in future combination studies of REGN5093 with other therapies.
    Clinical • Metastases
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • JAK2 (Janus kinase 2)
    |
    EGFR mutation • BRAF mutation • MET amplification • KRAS G12D • PIK3CA H1047R • MET exon 14 mutation • MET overexpression • MET mutation • MET expression • KRAS G12 • JAK2 V617F • TP53 R248Q • EGFR mutation + MET-CEP7 fusion • MET Y1230C • MET D1228H • MET Y1230C
    |
    FoundationOne® CDx • TruSight Oncology 500 Assay
    |
    davutamig (REGN5093)
    over1year
    Randomized Trial of Tepotinib Plus Gefitinib Versus Chemotherapy in EGFR-Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final Analysis. (PubMed, Clin Cancer Res)
    Final analysis of INSIGHT suggests improved PFS and OS with tepotinib plus gefitinib versus chemotherapy in a subgroup of patients with MET-amplified EGFR-mutant NSCLC, after progression on EGFR inhibitors.
    Journal
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    EGFR mutation • MET amplification • MET mutation • EGFR mutation + MET amplification • EGFR mutation + MET-CEP7 fusion
    |
    gefitinib • Tepmetko (tepotinib)
    over1year
    Phase 1b study of HS-10241 combined with almonertinib in pre-treated advanced non-small cell lung cancer (NSCLC) harboring EGFR mutation. (ASCO 2023)
    HS-10241 in combination with almonertinib was well tolerated, and showed encouraging antitumor activity in treatment of advanced NSCLC with EGFR mutation and MET amplification following prior EGFR-TKI, whether MET GCN ≥10 or MET GCN ≥5 but < 10. Clinical trial information: NCT05430386.
    P1 data • Metastases
    |
    EGFR (Epidermal growth factor receptor) • MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    EGFR mutation • MET amplification • MET mutation • MET amplification + EGFR mutation • EGFR mutation + MET amplification • EGFR mutation + MET-CEP7 fusion
    |
    Ameile (aumolertinib) • HS-10241